Cubist Systematic Strategies, LLC Adaptimmune Therapeutics PLC Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.7 - $1.75 $448,892 - $1.12 Million	641,275 Added 1853.02%	675,882 $1.07 Million
Q4 2023 Feb 14, 2024	BUY	$0.43 - $0.79 $14,881 - $27,339	34,607 New	34,607 $27,000
Q2 2023 Aug 14, 2023	SELL	$0.9 - $1.51 $2,266 - $3,802	-2,518 Reduced 20.04%	10,049 $9,000
Q1 2023 May 15, 2023	SELL	$1.06 - $2.16 $10,664 - $21,731	-10,061 Reduced 44.46%	12,567 $13,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $23,759 - $57,248	22,628 New	22,628 $33,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $56,000 - $96,001	-42,106 Reduced 95.26%	2,094 $4,000
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $62,835 - $147,463	-36,321 Reduced 45.11%	44,200 $91,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $78,988 - $128,186	22,568 Added 38.94%	80,521 $302,000
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $165,305 - $306,103	48,054 Added 485.44%	57,953 $300,000
Q2 2021 Aug 16, 2021	BUY	$3.86 - $5.78 $21,998 - $32,940	5,699 Added 135.69%	9,899 $42,000
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $85,661 - $119,402	-17,482 Reduced 80.63%	4,200 $22,000
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $86,728 - $199,474	21,682 New	21,682 $117,000
Q3 2020 Nov 16, 2020	SELL	$7.66 - $10.78 $151,239 - $212,840	-19,744 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $50,939 - $238,902	19,744 New	19,744 $198,000
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $55,295 - $92,311	-15,233 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $13,129 - $49,446	3,492 Added 29.74%	15,233 $88,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $71,146 - $116,656	-8,603 Reduced 42.29%	11,741 $159,000
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $23,663 - $31,203	-2,271 Reduced 10.04%	20,344 $241,000
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $23,039 - $37,512	3,245 Added 16.75%	22,615 $254,000
Q4 2017 Feb 14, 2018	SELL	$6.68 - $8.74 $18,697 - $24,463	-2,799 Reduced 12.63%	19,370 $129,000
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $109,293 - $197,969	22,169	22,169 $182,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

Matrix Capital Management Company, LP Waltham, MA

37.7M
Shares

$22.2 Million
1.71% of portfolio
Eco R1 Capital, LLC San Francisco, CA

27.4M
Shares

$16.2 Million
1.13% of portfolio
Nea Management Company, LLC Timonium, MD

17.1M
Shares

$10.1 Million
1.24% of portfolio
Baillie Gifford & CO

16.8M
Shares

$9.9 Million
0.01% of portfolio
Long Focus Capital Management, LLC San Juan, PR

13.3M
Shares

$7.85 Million
0.46% of portfolio

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account